Top losers — mid+ cap, diena -10% ar daugiau

2026-10-25 13:12
Atnaujinta: 2026-10-25 13:12

Top losers mid+ cap, diena -10% ar daugiau

Šaltinis: Atidaryti ↗
LKQY📊📈LKQ Corp
17.42 USD -22.47%
Auto Parts · $4.4B
MCap $4.4B  |  EV $9.4B  |  P/E 9.2  |  Fwd P/E 5.7  |  Div 6.89%  |  Cash/sh $1.19  |  EPS $1.89  |  EPS next Y $3.06  |  EPS š.m. -29.0%  |  EPS kiti m. +15.4%
RSI 22.1  |  SMA20 $22.02  |  SMA50 $23.53  |  SMA200 $27.07  |  Vol (sav.) 10.6%  |  Vol (mėn.) 5.2%
💰 PINIGŲ SRAUTAS · 2025
PAJAMOS13.7BCOGS8.4B · 61%OpEx4.2B · 31%Mokesčiai / kita480M · 4%Grynasis pelnas607M · 4%
💵 CASH FLOW● operacinė ● investicinė ● finansavimo
1.2B172M-1.4B2022FCF 1B1.4B-2.4B1.1B2023FCF 998M1.1B-406M-746M2024FCF 810M1.1B185M-1.2B2025FCF 847M
1 mėn.S $17.21R $22.87O:18.2 H:18.3 L:17.2 C:17.4 V:23.4M1 mėn. -26.1%
1 m.S $22.52R $26.96O:25.1 H:25.7 L:25.1 C:25.5 V:2.3M1 m. -13.3%
5 m.S $27.53R $42.21O:30.1 H:30.1 L:28.4 C:28.8 V:77.1M5 m. -41.3%
Dienos zvakes + Bollinger Bands (realus laikas)
1sav -21.64%
1mėn -24.26%
3mėn -33.64%
YTD -42.32%
Vol 23.41M
RelVol 6.84
⚡ AI ANALIZĖ
LKQ krito ~10–16 % po preliminarių Q3 rezultatų: organinės pajamos -5,4 % metams, Europa ypač silpna (-9,8 %; ERP diegimo problemos Vokietijoje, silpnas UK/Benelux), atšaukti visų 2026 m. gidai ir išvyksta CEO. Tai aiški fundamentinė neigiama žinia, ne techninis judėjimas. Rizikos: ERP sutrikimai Europoje gali tęstis kelis ketvirčius, o gydų atšaukimas palieka investuotojus be orientyrų. Katalizatoriai: pilna Q3 ataskaita, naujo CEO paskyrimas ir ERP stabilizavimo signalai.
RGCY📊📈Regencell Bioscience Holdings Ltd
7.67 USD -21.81%
Drug Manufacturers - Specialty & Generic · $3.8B
MCap $3.8B  |  EV $3.8B  |  P/E –  |  Fwd P/E –  |  Div –  |  Cash/sh $0.03  |  EPS $-0.02  |  EPS next Y –  |  EPS š.m. –  |  EPS kiti m. –
RSI 52.6  |  SMA20 $7.99  |  SMA50 $6.68  |  SMA200 $17.96  |  Vol (sav.) 11.6%  |  Vol (mėn.) 8.0%
💵 CASH FLOW● operacinė ● investicinė ● finansavimo
-5M-11M22M2022FCF -6M-5M59K135K2023FCF -5M-4M5M102K2024FCF -4M-8M3M17M2026FCF -8M
1 mėn.S $6.46R $11.31O:9.8 H:9.8 L:7.6 C:7.7 V:0.5M1 mėn. +26.2%
1 m.S $4.67R $17.92O:6.4 H:7.7 L:6.3 C:6.9 V:0.7M1 m. -57.7%
5 m.S $0.09R $28.00O:16.8 H:20.0 L:16.3 C:19.8 V:1.0M5 m. +4778.7%
Dienos zvakes + Bollinger Bands (realus laikas)
1sav -20.02%
1mėn +24.31%
3mėn +31.56%
YTD -63.48%
Vol 476.6K
RelVol 1.99
⚡ AI ANALIZĖ
Regencell Bioscience nukrito ~22 % be jokios naujos fundamentinės žinios — paskutinis įvykis buvo metinė 20-F ataskaita spalio 8 d. Tai tipinis spekuliatyvus judėjimas: maža kapitalizacija (tarp $4–5 mlrd. vertinimo ir realių nuostolingų klinikinių tyrimų tradicinės kinų medicinos srityje) ir labai svyrantis retail srautas. Rizikos: DOJ tyrimas dėl finansų, $500 mln. ATM dilucijos programa ir neigiama EPS — kaina gali kristi dar greičiau nei kyla. Artimų katalizatorių nėra; čia veikia tik sentimentas ir momentum prekyba.
CORTY📊📈Corcept Therapeutics Inc
85.86 USD -20.13%
Biotechnology · $9.3B
MCap $9.3B  |  EV $9.0B  |  P/E 190.8  |  Fwd P/E 19.5  |  Div –  |  Cash/sh $2.85  |  EPS $0.45  |  EPS next Y $4.41  |  EPS š.m. +24.1%  |  EPS kiti m. +107.8%
RSI 16.6  |  SMA20 $114.69  |  SMA50 $115.21  |  SMA200 $73.55  |  Vol (sav.) 9.8%  |  Vol (mėn.) 5.0%
💰 PINIGŲ SRAUTAS · 2025
PAJAMOS761MCOGS13M · 2%OpEx704M · 92%Grynasis pelnas100M · 13%
💵 CASH FLOW● operacinė ● investicinė ● finansavimo
120M-114M-17M2022FCF 120M127M91M-149M2023FCF 127M198M-178M-28M2024FCF 196M142M70M-220M2025FCF 142M
1 mėn.S $84.13R $122.81O:106.1 H:106.1 L:84.1 C:85.9 V:3.1M1 mėn. -23.2%
1 m.S $79.22R $126.38O:110.6 H:112.1 L:109.3 C:111.6 V:0.6M1 m. +51.7%
5 m.S $49.00R $89.00O:88.7 H:89.0 L:78.1 C:83.8 V:8.1M5 m. +348.9%
Dienos zvakes + Bollinger Bands (realus laikas)
1sav -22.06%
1mėn -27.55%
3mėn -5.77%
YTD +146.72%
Vol 3.10M
RelVol 2.60
🤖 TradingAgents CFD: NIEKO NEDARYTI (ataskaita nuo 2026-10-02, prieš 23 d.) pilna ataskaita ↗
Hold
🎫 Trade Plan
🎯 Action: Hold💵 Entry: –🛑 Stop: 109.0
Position sizing:

Maintain current allocation; cap position at a size the portfolio could withstand through a 25–30% adverse catalyst gap. Do not add.

Reasoning:

CORT's secular uptrend remains intact (price 63% above the 200 SMA at $69.78, 50 SMA rising every session to $112.61) and the five-week flag between ~$108 and $120 shows bullish consolidation behavior (RSI 50.5 holding the 45–58 band, no distribution volume). However, short-term momentum has rolled over — price sits below the 10 EMA ($114.80), MACD has crossed below signal with a negative histogram, and repeated failures above $120 warn that timing for new longs is unconfirmed. The research plan's fundamentals are mixed (strong Korlym franchise and cash position versus unproven Lifyorli ramp, 97% receivables growth, and dependence on year-end FDA/EMA binary events), so neither aggressive initiation nor exit is warranted. Hold existing exposure with a protective stop just below the $108–110 support shelf (~2x ATR under the mid-band, a $109 stop is ~4.4% below the $114.03 close); a decisive close below that shelf triggers the planned 25–33% reduction, while adds require confirmed breakout above ~$120.5 plus Q3 revenue, receivables, and regulatory validation.

📊 Techninė analizė (5)
Executive Summary

CORT has undergone a massive, sustained uptrend — roughly tripling from ~$40 in early April 2026 to a peak of ~$123.57 (2026-08-25) — and has spent the last ~5 weeks in a high-level consolidation/bullish flag between roughly $108 and $120. The stock sits at a decision point: the long-term trend remains powerfully bullish, but short-term momentum has stalled and is actively deteriorating at the margins.

Indicators selected (8, non-redundant): `close_200_sma`, `close_50_sma`, `close_10_ema`, `macd` (+ signal/histogram read from the verified snapshot), `rsi`, `boll` (middle, with upper/lower bands from snapshot), `atr`, `vwma`. This set spans trend (3 horizons), momentum (2), volatility/range (2), and volume-price confirmation (1) — each answering a distinct question about the current regime.

---

Trend Analysis (MA)

| Horizon | Indicator (10-01 value) | Price Relationship | Interpretation |

|---|---|---|---|

| Long-term | 200 SMA: $69.78 | Price +63% above | Secular uptrend fully intact |

| Medium-term | 50 SMA: $112.61 | Price +1.2% above | Trend intact but flattening base |

| Short-term | 10 EMA: $114.80 | Price −0.7% below | Momentum has rolled over |

  • The 50 SMA has risen every single session from $84.82 (08-03) to $112.61 (10-01) — an unbroken ~$28 climb over two months. This is a strong dynamic support shelf. The 200 SMA has similarly ground higher from $62.01 to $69.78. There is no death-cross risk whatsoever; the moving-average stack remains perfectly ordered (10 EMA > 50 SMA > 200 SMA).
  • Key nuance: price closed at $114.03, marginally below the 10 EMA ($114.80) for the most recent session after oscillating around it since mid-September. The 10 EMA itself has gone flat (~$114.8–115.0 for the last week), confirming short-term momentum exhaustion rather than active distribution.
  • The 50 SMA at ~$112.6 and the VWMA at ~$113.1 form a confluent support zone ($112.5–113.5) that has absorbed every pullback since early September.

Verdict: Strategic trend = bullish. Tactical trend = neutral/slightly soft.

Momentum (MACD & RSI)
  • RSI: 50.54 — dead-neutral. This is a dramatic normalization from the 72+ readings in late August (peak overbought zone 08-21 to 08-25). Importantly, during the entire September consolidation RSI has held the 45–58 band, never dipping below ~46.6 (09-18). This is classic bullish consolidation behavior — sellers have been unable to push momentum into oversold territory.
  • MACD: 0.89 vs. Signal 1.09 → Histogram −0.20 — the MACD line crossed below its signal line and the histogram has gone negative. The MACD line has collapsed from a peak of 7.23 (08-25) to 0.89 — a ~88% decay. While MACD remains above zero (no trend-reversal signal), the bearish crossover warns that upside impetus has faded. Momentum traders should treat this as a yellow flag, not a sell trigger, given the zero-line support.
Volatility (BB & ATR)
  • ATR: 5.23 — down from 6.06 (08-03) and well off the spike highs seen around the 07-30 gap (the $92.95→$118.32 candle on 4.5M volume). Volatility is contracting as the flag forms — typical and constructive.
  • Bollinger snapshot: Middle $113.99 | Upper $118.33 | Lower $109.65 — price ($114.03) sits essentially on the mid-band, with the bands relatively tight (bandwidth ≈ 7.6% of price). The market is coiling. The late-August breakdown from the upper band (~$126) to the lower region was orderly, and price has since mean-reverted to the middle — equilibrium.
  • Notable: the 09-18 session printed 17.23M volume (vs. typical ~0.6–1.5M) with a wide range ($108.41–$117.90) closing at $110.29 — an institutional-scale churn day that resolved sideways rather than downward, suggesting absorption.
Actionable Insights

Support levels (evidence-based):

  • $112.5–113.5 — 50 SMA ($112.61) + VWMA ($113.10) confluence; also the 09-08 and 09-23 reaction lows zone.
  • $109.6–110.8 — Bollinger lower band ($109.65) + the 09-18 ($110.29) and 09-15 ($110.82) closes.
  • A decisive break of ~$108 (lower band region, 09-02 low $108.73) would target the rising 50 SMA gap-fill toward $105, and potentially the $100 round number.

Resistance levels:

  • $118.3 — Bollinger upper band + 09-24 high ($119.15) + 09-29 high ($120.51) zone.
  • $120.4–123.6 — 09-25 high ($120.44), 08-24/08-25 double-top ($123.24/$123.57). A breakout above $123.57 on expanding volume re-opens the trend.

Trade plan:

  • Existing holders (HOLD): the secular uptrend and orderly consolidation argue for patience. A trailing stop below the $108–110 zone (roughly 2× ATR under the mid-band) protects against a trend break while allowing the flag to resolve.
  • New entries: momentum traders should wait for either (a) a close above ~$118.3–120.5 with MACD histogram turning positive, or (b) a pullback to the $110–112.5 shelf where RSI resets toward 40–45 with a bullish reversal candle.
  • Risk: biotech headline risk is inherent; position size per ATR (5.23 ≈ 4.6% of price) — e.g., a $109 stop is ~4.4% below current price.
⚡ AI ANALIZĖ
Corcept Therapeutics krenta (~-5–20 %) po dviejų smūgių: FDA Complete Response Letter relacorilantui (hiperkortizolizmo hipertenzijai) bei konkurento Genmab stiprių vėžio duomenų, kurie sumenko relacorilanto klinikinės programos lūkesčius. Tai fundamentinė, ne techninė naujiena — pagrindinio augimo variklio (Korlym įpėdinio) ateitis suklausta, akcija jau buvo kritusi >50 % nuo piko. Rizikos: gali prireikti papildomo brangaus klinikinio tyrimo; analitikai (Canaccord) nuleido tikslus. Katalizatoriai: susitikimas su FDA dėl CRL priežasčių ir relacorilanto onkologijos programos duomenys.
TNGXY📊📈Tango Therapeutics Inc
23.34 USD -16.43%
Biotechnology · $3.9B
MCap $3.9B  |  EV $3.0B  |  P/E –  |  Fwd P/E -14.0  |  Div –  |  Cash/sh $6.01  |  EPS $-0.85  |  EPS next Y $-1.67  |  EPS š.m. –  |  EPS kiti m. -19.5%
RSI 50.8  |  SMA20 $23.75  |  SMA50 $23.85  |  SMA200 $22.05  |  Vol (sav.) 10.2%  |  Vol (mėn.) 5.6%
💰 PINIGŲ SRAUTAS · 2025
PAJAMOS62MOpEx174M · 278%Grynasis nuostolis102M · 163%
💵 CASH FLOW● operacinė ● investicinė ● finansavimo
-109M26M2M2022FCF -117M-118M41M82M2023FCF -120M-132M86M48M2024FCF -132M-139M-41M222M2025FCF -140M
1 mėn.S $20.98R $27.98O:25.5 H:25.9 L:22.7 C:23.3 V:15.9M1 mėn. -2.7%
1 m.S $22.29R $33.14O:22.5 H:22.9 L:22.3 C:22.5 V:1.5M1 m. +187.2%
5 m.S $1.03R $10.08O:9.5 H:10.1 L:8.4 C:8.5 V:21.0M5 m. -36.4%
Dienos zvakes + Bollinger Bands (realus laikas)
1sav +5.90%
1mėn -5.24%
3mėn -12.65%
YTD +163.43%
Vol 15.85M
RelVol 5.40
⚡ AI ANALIZĖ
Tango Therapeutics krito nors spalio 23 d. pristatė teigiamus 1/2 f. vopimetostat + daraxonrasib kasos vėžio duomenis — klasikinis „sell the news“ po ~250 % kilimo nuo metų pradžios; sesijos metu kaina svyravo $22,7–29,7 su trigubai didesne apyvarta. Tai daugiau techninis pelno fiksavimas, bet ir vertinimo argumentas (MCap ~$3,9 mlrd. be pajamų). Rizikos: biotech be produkto, finansavimo poreikis ir didelis short float jautrumas. Katalizatoriai: programos plėtimo planai, bendradarbiavimo (Revolution Medicines) naujienos ir kiti klinikiniai duomenys.
BEY📊📈Bloom Energy Corp
193.30 USD -11.24%
Electrical Equipment & Parts · $56.9B
MCap $57.1B  |  EV $57.5B  |  P/E 254.3  |  Fwd P/E 39.1  |  Div –  |  Cash/sh $8.41  |  EPS $0.76  |  EPS next Y $4.94  |  EPS š.m. –  |  EPS kiti m. +62.7%
RSI 22.7  |  SMA20 $257.30  |  SMA50 $248.30  |  SMA200 $219.29  |  Vol (sav.) 7.6%  |  Vol (mėn.) 6.2%
💰 PINIGŲ SRAUTAS · 2025
PAJAMOS2BCOGS1.4B · 71%OpEx515M · 25%Mokesčiai / kita161M · 8%Grynasis nuostolis88M · 4%
💵 CASH FLOW● operacinė ● investicinė ● finansavimo
-192M-117M211M2022FCF -309M-373M-84M683M2023FCF -456M92M-59M175M2024FCF 33M114M-93M1.5B2025FCF 57M
1 mėn.S $189.00R $300.80O:203.0 H:206.0 L:189.0 C:193.3 V:35.9M1 mėn. -24.5%
1 m.S $157.65R $329.69O:236.8 H:253.3 L:235.6 C:252.9 V:16.5M1 m. +138.6%
5 m.S $15.15R $119.60O:96.5 H:97.0 L:75.7 C:88.8 V:78.3M5 m. +251.8%
Dienos zvakes + Bollinger Bands (realus laikas)
1sav -12.66%
1mėn -27.51%
3mėn +2.72%
YTD +122.47%
Vol 36.02M
RelVol 2.30
⚡ AI ANALIZĖ
Bloom Energy krito ~11 % nepaisant rekordinių Q3 rezultatų ir pakeltų gidų — rinką gąsdino pinigų srautų konversija ir vertinimas po milžiniško kilimo; prisidėjo bendras AI infrastruktūros akcijų išpardavimas. Tai mišrus judėjimas: fundamentai (paklausą varo duomenų centrai, netrukus įtraukimas į S&P 500) stiprūs, bet vertinimas labai pritemptas. Rizikos: neigiami laisvi pinigų srautai ir jautrumas AI capex nuotaikoms. Katalizatoriai: S&P 500 įtraukimo indeksų pirkimai ir laisvų pinigų srautų pagerėjimas artimiausiais ketvirčiais.
SLMY📊📈SLM Corp
19.42 USD -10.78%
Credit Services · $3.6B
MCap $3.7B  |  EV $8.0B  |  P/E 7.0  |  Fwd P/E 6.4  |  Div 2.68%  |  Cash/sh $12.07  |  EPS $2.79  |  EPS next Y $3.05  |  EPS š.m. –  |  EPS kiti m. +49.3%
RSI 26.1  |  SMA20 $22.33  |  SMA50 $24.44  |  SMA200 $23.57  |  Vol (sav.) 5.8%  |  Vol (mėn.) 3.0%
💰 PINIGŲ SRAUTAS · 2025
PAJAMOS2BMokesčiai / kita1.2B · 62%Grynasis pelnas745M · 38%
💵 CASH FLOW● operacinė ● investicinė ● finansavimo
5M1.1B-855M2022FCF 5M-145M-12M-316M2023FCF -145M-329M676M228M2024FCF -329M-399M1B-1.1B2025FCF -399M
1 mėn.S $19.12R $23.48O:20.8 H:21.0 L:19.1 C:19.4 V:13.0M1 mėn. -17.7%
1 m.S $21.99R $28.13O:26.1 H:27.2 L:26.0 C:27.1 V:1.8M1 m. -7.1%
5 m.S $22.86R $33.37O:26.6 H:27.0 L:26.0 C:26.9 V:18.6M5 m. +61.0%
Dienos zvakes + Bollinger Bands (realus laikas)
1sav -10.98%
1mėn -15.77%
3mėn -23.62%
YTD -28.25%
Vol 12.98M
RelVol 5.39
⚡ AI ANALIZĖ
SLM (Sallie Mae) krito ~9 % po Q3 rezultatų: sumažinti metų gidai dėl kredito kokybės gerinimo priemonių, kurios laikinai spaudžia pajamas. Tai fundamentinė naujiena, bet dalis analitikų (Simply Wall St) mato akciją kaip neįvertintą po gidų „reset“ — kaina ~$22,6 prieš 52 sav. maksimumą $31. Rizikos: privačių studentų paskolų kredito ciklas ir palūkanų aplinka. Katalizatoriai: dividendų tęstinumas (būtent paskelbti preferred ir common dividendai spalio 13 d.) ir kredito rodiklių gerėjimas Q4.